Biotech Business Advises on Preclinical Collaboration to Evaluate Potential Novel Vaccine Adjuvants
December - 2018
Biotech Business recently advised one of our clients on a preclinical collaboration with the National Institute of Biological Standards and Controls in the UK. The collaboration will evaluate the activity of novel immunomodulatory molecules as potential adjuvants for use in combination with vaccines against certain bacterial infections. Further details are confidential.